Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial

Shulman, M., Provost, S., Ohrtman, K., Novo, P., Meyers-Ohki, S., Van Veldhuisen, P., Oden, N., Otterstatter, M., Bailey, G. L., Liu, D., Rotrosen, J., Nunes, E. V., & Weiss, R. D. (2024). Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemporary Clinical Trials, 142, 107543. https://doi.org/10.1016/j.cct.2024.107543
Authors:
Matisyahu Shulman
Scott Provost
Kaitlyn Ohrtman
Patricia Novo
Sarah Meyers-Ohki
Paul Van Veldhuisen
Neal Oden
Michael Otterstatter
Genie L Bailey
David Liu
John Rotrosen
Edward V Nunes
Roger D Weiss
Affiliated Authors:
Matisyahu Shulman
Edward V Nunes
Columbia Affiliation:
Subjects:
Buprenorphine (MeSH)
Opioid-Related Disorders (MeSH)
Naltrexone (MeSH)
Delayed-Action Preparations (MeSH)
Author Keywords:
treatment
opioids
buprenorphine
naltrexone
opioid use disorder
automated psychosocial intervention
elink
Publication Type:
Article
Unique ID:
10.1016/j.cct.2024.107543
PMID:
38657730
DOI:
10.1016/j.cct.2024.107543
Journal:
Contemporary Clinical Trials
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: